LRP1B mutation is associated with tumor immune microenvironment and progression-free survival in lung adenocarcinoma treated with immune checkpoint inhibitors

BACKGROUND: Only a fraction of lung adenocarcinoma (LUAD) patients are eligible for immunotherapy. The identification of biomarkers for immunotherapy is crucial to improve patient outcomes. This study aims to systemically analyze LRP1B mutation and its association with the tumor immune microenvironm...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Ziyi, Feng, Wei, Wang, Yuxuan, Shi, Liang, Gong, Yuhui, Shi, Yichao, Shen, Shiyu, Huang, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088005/
https://www.ncbi.nlm.nih.gov/pubmed/37057124
http://dx.doi.org/10.21037/tlcr-23-39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088005/
https://www.ncbi.nlm.nih.gov/pubmed/37057124
http://dx.doi.org/10.21037/tlcr-23-39

Ejemplares similares